211
Participants
Start Date
May 24, 2020
Primary Completion Date
February 26, 2021
Study Completion Date
February 26, 2021
Placebo
Placebo administered BID approximately 12 hours apart
Ruxolitinib
Ruxolitinb administered BID approximately 12 hours apart
University of Rochester Medical Center, Rochester
Allegheny Health Network, Wexford
West Penn Hospital, Pittsburgh
Jefferson University Hospitals, Philadelphia
Temple University, Philadelphia
Georgetown University Hospital, Washington D.C.
Johns Hopkins University, Baltimore
Duke University Medical Center, Durham
East Carolina University, Greenville
University of Florida, Gainesville
Teradan Clinical Trials, Brandon
Tampa General Hospital, Tampa
University of South Florida, Tampa
University of Cincinnati, Cincinnati
Kettering Cancer Care, Dayton
Indiana University Simon Cancer Center, Indianapolis
Indiana University Health Central Indiana Cancer Centers, Indianapolis
Aurora Research Institute, Milwaukee
Healthpartners Cancer Care Center - Regions Hospital, Saint Paul
Loyola University Medical Center, Maywood
Northshore University Health System, Chicago
Mercy Research, Springfield
East Jefferson General Hospital, Metairie
University of Texas Health Science Center At Houston - McGovern Medical School, Houston
University of Texas Health Science Cente, San Antonio
St David'S Medical Center, Austin
Honor Health Research Institute, Scottsdale
Sharp Memorial Hospital, San Diego
Wenatchee Valley Hospital and Clinics, Wenatchee
Sbih City Hospital 15, Saint Petersburg
Boston Medical Center, Boston
Lahey Hospital & Medical Center, Burlington
University of Massachusetts Medical School, Worcester
Hackensack University Medical Center, Hackensack
Rutgers Njms Clinical Research Unit, Newark
Holy Name Medical Center, Teaneck
Lead Sponsor
Incyte Corporation
INDUSTRY